FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose Safety Announcement[removed]The U.S. Food and Drug Administration (FDA) is warning that - Cyclopyrrolones - Document - PDFSEARCH.IO

First Page	Meta Content
	FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose Safety Announcement[removed]The U.S. Food and Drug Administration (FDA) is warning that Add to Reading List Open Document File Size: 63,11 KB Share Result on Facebook Country United States / / Event Product Issues / / IndustryTerm generic eszopiclone products / retail / / MedicalCondition severe liver disease / insomnia / Sleep Disorder / prescription insomnia / similar insomnia / consistent psychomotor impairment / / Organization FDA / U.S. Food and Drug Administration / / Product Lunesta / activities / other activities / / PublishedMedium the Medication Guide / / SocialTag Nonbenzodiazepines Cyclopyrrolones Carbamates Pyridines Eszopiclone Zopiclone Flunitrazepam Sedative Insomnia Chemistry

FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose Safety Announcement[removed]The U.S. Food and Drug Administration (FDA) is warning thatAdd to Reading List